posture. Eighteen patients (4 men and 14 women) whose preoperative posture score was 2 or more in the medication-on state were enrolled in this study. We retrospectively reviewed the clinical course of these 18 patients. Clinical assessments with UPDRS III motor score were performed preoperatively, at 1 month, and at 12 months after surgery.
Surgical Procedure
Quadripolar DBS electrodes (Activa 3389, Medtronic) were implanted bilaterally with stereotactic guidance after induction of local anesthesia. The target localization was based on the Schaltenbrand-Wahren atlas and on direct visualization on the MR image by using surgical planning software (Frame Link, Medtronic). The target was refined physiologically by intraoperative microelectrode recording. Subsequently, internal pulse generators (Soletra, Medtronic) were placed in infraclavicular pockets and subcutaneously connected to the DBS leads after induction of general anesthesia.
Adjusting Stimulation Parameters and Medication
Electrical stimulation began a few days after surgery. Stimulation parameters were adjusted to produce maximal clinical benefit for cardinal PD symptoms without side effects. Preferably, a monopolar electrode setting was used, unless stimulator-induced side effects required a more focal bipolar stimulation paradigm. In most cases, stimulation parameters were 90 msec of pulse width, 130 Hz of pulse rate, and 2-3 V of amplitude. After surgery, dopaminergic medication was initially reduced by approximately 50%, and then further adjusted based on stimulation-induced improvements of PD symptoms.
The levodopa-equivalent dosage calculations were adapted as follows: 100 mg levodopa with a dopa carboxylase inhibitor = 1 mg pergolide = 10 mg bromocriptine = 1.5 mg pramipexole = 9 mg ropinirole = 4 mg cabergoline. Nondopaminergic therapy (anticholinergics and amantadine) was not included in the calculation.
Results

Patient Demographics
The demographic details for all patients are shown in Table 1 . The mean age of the patients at the time of surgery was 65.2 years (range 56-79 years), and the mean duration of the disease was 13.4 years (range 5-20 years). Eight patients (Cases 1-8) were considered to have camptocormia, and 10 patients (Cases 9-18) were considered to have Pisa syndrome. Nine patients (Cases 2, 3, 8-10, 14, and [16] [17] [18] showed apparent thoracolumbar spinal deformity such as spondylosis or dislocation on radiography. The severity of postural abnormality in the medicationon period was considered moderate (score of 2 on item 28) in 13 patients (Cases 1-6 and 9-15) and severe (score of 3 or 4 on item 28) in 5 patients (Cases 7, 8, and [16] [17] [18] . Most patients had significant motor fluctuations caused by levodopa, except the one in Case 16. Ten patients (Cases 2-7, 13-15, and 17) had levodopa responsiveness in terms of postural abnormality before surgery.
Outcome of STN DBS
Bilateral DBS of the STN yielded marked improvement in the UPDRS III motor score in the "medicationoff" state and reduced of the need for dopaminergic medication in most patients.
Bilateral STN DBS yielded improvement of both camptocormia and Pisa syndrome ( Figs. 1 and 2 ). In 13 patients with moderate postural abnormality (score of 2 on UPDRS III item 28), 9 (Cases 1-4 and 9-13) improved soon after surgery, but 1 patient (Case 1) deteriorated again. Two patients (Cases 5 and 14) improved gradually over a long period after surgery, whereas 2 (Cases 6 and 15) did not improve at all. In 5 patients with severe postural abnormality (a score of 3 or 4 on UPDRS III item 28), 2 (Cases 7 and 17) improved slightly in the long-term follow-up period after surgery, but 3 patients (Cases 8, 16, and 18) did not improve at all.
Regarding complications of STN DBS, 1 patient (Case 13) had severe skin erosion at the site of the internal pulse generator and required surgical repair. One patient (Case 12) suffered from prolonged depression in spite of improvement of motor function and posture.
Factors Affecting Outcome
We analyzed the factors affecting the outcome of postural abnormality. These factors were as follows: the type of abnormality (camptocormia or Pisa syndrome); its severity (moderate or severe); thoracolumbar spinal deformity; preoperative levodopa responsiveness; and reduction of dopaminergic medication after STN DBS (Table 2 ). Only the severity of postural abnormality was a factor related to early improvement of this condition after STN DBS (p < 0.05). Moderate rather than severe postural abnormality tended to improve in the early stage after surgery.
Discussion
Pathogenesis of Postural Abnormality in PD
Parkinson disease often accompanies various postural abnormalities. According to a recent report, the incidence is 12.2% in camptocormia, and 8.5% in scoliosis.
1
Postural abnormality causes disability in many patients with PD. Regarding the pathogenesis of postural abnormality in patients with PD, severe rigidity or dystonia in paraspinal muscles is considered to cause the abnormality.
Camptocormia is one of most disabling symptoms of PD and other parkinsonian disorders. The clinical features of camptocormia in PD include old age, predominant occurrence in males, long duration of the disease, and early axial involvement. 6 Most patients have spondyloarthrotic changes in the spine and complain of mildto-moderate low-back pain.
12 Various mechanisms may contribute to the development of camptocormia in PD. Parkinsonian camptocormia could be the consequence of axial rigidity of the flexion muscles due to dysfunction of the basal ganglia controlling the reticulospinal pathway.
12
Another possibility is that camptocormia is an action dystonia involving the rectus abdominus or thoracolumbar * LED = levodopa-equivalent dosage; Meds = medications; + = present; − = absent. 
muscles.
1,13 Dystonia is common in patients with PD. In addition, it has been suggested that camptocormia may be due to myopathy of the antigravity muscles associated with trunk extension. 15 In most patients, levodopa therapy does not ameliorate camptocormia as it does other axial symptoms of PD. However, dopaminergic therapy can resolve camptocormia in some patients, which suggests that a variety of dopaminergic mechanisms may be involved in the pathogenesis of this entity in patients with PD.
10
Pisa syndrome was first described in association with prolonged use of neuroleptic, antiemetic, or cholinesterase inhibitors. 1, 3, 11, 20 Pisa syndrome induced by neuroleptics is characterized not by trunk rigidity, but by dystonia in the trunk muscles. In addition, some studies have reported that several patients with PD have spontaneously developed Pisa syndrome as a form of axial dystonia. The volume of the paraspinal muscles contralateral to the side of lateral flexion is larger than in those ipsilateral to the side of this abnormal posture, and this pathological enlargement of the muscle might be a sign caused by dystonia.
20
This finding indicates that this postural abnormality in patients with PD has a component of dystonia in addition to rigidity. Pisa syndrome may be a form of axial dystonia derived from the striatal imbalance between an excess of cholinergic neurotransmission and a decrease of dopaminergic neurotransmission.
11,18
In addition, side effects of dopamine agonist are also mentioned as a cause of postural abnormalities such as the dropped head, forward flexion, or lateral flexion of the body. Cannas et al. 5 reported the development of reversible Pisa syndrome in a patient with PD during treatment of pergolide. Nondopaminergic effects of pergolide at the level of serotonergic/adrenergic receptors might have played a pathogenic role in their patient. Suzuki et al. 16 and Taguchi et al. 17 documented subacute onset of pramipexole-induced dropped head in patients with PD. Therefore, if postural abnormality appears during medical treatment, the dopamine agonist should be discontinued or changed.
Effect of STN DBS for Postural Abnormality in PD
There are some previous case reports concerning the effect of DBS for postural abnormality in patients with PD (Table 3) . 2, 9, 14, 15, 19 These reported cases all involve camptocormia. The target of DBS was the globus pallidus internus in 1 case and the STN in 4 cases. Three cases were treated successfully with DBS, but 2 did not improve. Recovery time varied from immediately to 6 months after surgery. In the present series, we performed STN DBS for the treatment of motor complications of levodopa and not for postural abnormality in most patients. However, our results also showed the possibility of STN DBS treatment for postural abnormality. Positive effects can be expected in the early stage after surgery in patients with slight or moderate postural abnormality (a score of 2 or less on UPDRS III item 28), even if spinal deformity is also present. Furthermore, severe postural abnormality (a score of 3 or more on UPDRS III item 28) also can be ameliorated gradually over a long period after surgery.
Regarding the role of STN DBS in the treatment of postural abnormality in patients with PD, improvement of rigidity and dystonia of paraspinal muscles by STN DBS seems to ameliorate postural abnormality. It is generally accepted that DBS ameliorates symptoms that respond to dopaminergic medications, but has no effect on other symptoms such as axial symptoms. However, most postural abnormalities responded favorably to DBS, as with the other levodopa-responsive symptoms. Deep brain stimulation of the STN has shown promise in the treatment of nondopaminergic PD-associated postural abnormality, and could emerge as the most reliable treatment for such difficult cases. Yamada et al. 19 posit that STN DBS-resistant camptocormia in patients with PD may result from peak-dose dystonia that appears in the thoracolumbar paraspinal muscles or camptocormia in relation to muscular disorders.
It seems that posture is formed not only by skeletal structure but also by paraspinal muscles. Therefore, if rigidity or dystonia of paraspinal muscles improves through STN DBS even in patients with skeletal deformity, there is still room for improvement of postural abnormality. Most severe postural abnormalities have been accompanied by severe spinal deformities. It would be physically difficult to expect complete improvement in these cases. Therefore, surgery should be considered before irreversible skeletal deformity develops.
Because a medication such as dopamine agonist may cause postural abnormality, reduction of the dopamine agonist after STN DBS may also be involved in its amelioration. In fact, dopaminergic medication could be significantly reduced after DBS in most cases in this series. However, no obvious relationship between the amelioration of postural abnormality and reduction of dopaminergic medication dose after STN DBS could be shown in this study. Postural abnormalities seem to have improved due to a direct effect of STN DBS for rigidity or dystonia, rather than indirectly through the effect of reduction of dopaminergic medication.
Conclusions
We studied the effect of STN DBS on postural abnormality in patients with PD. The STN DBS method can be used effectively to treat postural abnormalities including camptocormia and Pisa syndrome as well as cardinal symptoms of PD. For patients with slight or moderate postural abnormality (a score of 2 or less on UPDRS III item 28), a good outcome can be expected in the early postoperative stage. Most patients improved even when spinal deformity was also present. Severe postural abnormality (a score of 3 or more on UPDRS III item 28) also can be ameliorated gradually over a long period after surgery. However, surgery should be considered before irreversible skeletal deformity develops.
Disclaimer
The authors report no conflict of interest concerning the mate- 
